nContact Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s modifications to its VisiTrax cardiac ablation device, EPi-Sense, now with embedded sensing capability. This next generation of technology includes sensors along the ablation device, which provide real-time feedback to physicians conducting cardiac ablation procedures.

 

CardioMEMS Inc. has been honored as the 2012 recipient of the Intel Innovation Award. Founder and CEO Jay Yadav, M.D., was presented with the award on Dec. 4, 2012 during the annual Health IT Leadership Summit held at the historic Fox Theatre in Atlanta, Ga.


CardioKinetix Inc. announced the enrollment of the first patients in PARACHUTE IV, the randomized pivotal U.S. trial of the minimally invasive Parachute Ventricular Partitioning Device for the treatment of heart failure.


GSI Group Inc., a leading supplier of laser-based solutions, precision motion and optical technologies to global industrial, medical, electronics and scientific markets, announced that it has acquired NDS Surgical Imaging (NDS), a San Jose, Calif.-based global leader in surgical and radiology displays and related peripherals, for $82.5 million in cash, subject to customary closing adjustments.


Covidien began the commercial launch of the OneShot Renal Denervation System, an over the wire balloon-based irrigated ablation catheter technology for the treatment of hypertension.



The American Medical Association (AMA) submitted formal comments to the Office of the National Coordinator for Health Information Technology (ONC) on the Health IT Policy Committee’s proposal for Stage 3 of the Medicare/Medicaid meaningful use electronic health record (EHR) program requirements.


Open heart surgery may be a dying art, as new valve replacement techniques offer life-changing treatment without the need for invasive procedures, states a new report by healthcare experts GlobalData.

Lantheus Medical Imaging Inc. has added a low-enriched uranium (LEU) TechneLite (technetium Tc 99m Generator) generator to the its nuclear imaging product portfolio. Lantheus’ LEU TechneLite generator is the first technetium-99m (Tc-99m) generator in the United States that contains molybdenum-99 (Mo-99) produced from at least 95 percent LEU. With greater access to LEU Mo-99 through its supply chain diversification strategy, Lantheus can now move closer to its goal of eventually eliminating Highly Enriched Uranium (HEU)-sourced Mo-99 from its supply chain. Lantheus’ first LEU TechneLite generator was shipped on Jan. 7, 2013.

Subscribe Now